TICKERNERD
Menu
CADLCADLHealthcare · Biotechnology

CADL Stock Forecast: Candel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$9.66
−1.63% on the day

The 8 Wall Street analysts covering Candel Therapeutics, Inc. hold a median 12-month price target of $23 — +132.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$755.2M
Ticker Nerd rank
41 / 100
Median analyst target
$23
Analysts covering
8
Revenue$0.0
Operating income−$26.7M
Net income−$38.9M
Free cash flow−$17.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.9%
1M
−23.3%
YTD
+71.0%
1Y
+53.3%
From 52W high
−29.7%
From 52W low
+118.6%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CADL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Candel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
84
Value
78
Accruals
71
Quality
65
Size
48
Volatility
45
Revisions
26
Growth
21
Issuance
7

Momentum (84): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CADL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CADL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26CADLHigh $29Median $23Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $15Median $23High $29

The green dot is the last close — the median target sits +132.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Sept 2026B of A SecuritiesUpgradeBuy$12 → $18
14 Aug 2026B of A SecuritiesMaintainsNeutral$9.00 → $12
14 Aug 2026B of A SecuritiesMaintainsNeutral—
13 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
13 Aug 2026HC Wainwright & Co.ReiteratesBuy—
13 July 2026StifelInitiatesBuy$22
13 July 2026StifelInitiatesBuy—
20 Apr 2026Cantor FitzgeraldInitiatesOverweight—
18 Mar 2026CitigroupMaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026CitigroupMaintainsBuy—
8 Dec 2025Stephens & Co.ReiteratesOverweight—
21 Nov 2025Freedom BrokerMaintainsBuy—
14 Nov 2025CitigroupMaintainsBuy—
28 Oct 2025Stephens & Co.InitiatesOverweight—
21 Oct 2025LifeSci CapitalInitiatesOutperform—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025B of A SecuritiesDowngradeNeutral—
30 June 2025HC Wainwright & Co.AssumesBuy$23
11 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CADL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CADL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Candel Therapeutics, Inc. returned +53.3% against +16.2% for the S&P 500, dividends included.

CADL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26CADLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CADL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Candel Therapeutics, Inc. (CADL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.7×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
6.0×

Cheaper than 17% of US stocks

EV / EBITDA
−8.5×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 15% of US stocks

Return on assets
−28.6%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Candel Therapeutics, Inc. (CADL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Candel Therapeutics, Inc. has a market value of $755.2M and an enterprise value of $603.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$88.5M.

  • Diluted earnings per share, trailing twelve months: $−1.41.

  • Free cash flow in the twelve months to 30 June 2026: −$57.3M.

  • Shares outstanding: 76.1M.

  • Trailing P/E: −13.7×; forward P/E: −15.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Candel Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CADL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CADLCandel Therapeutics, Inc.$755.2M
41
DSGNDesign Therapeutics, Inc.$708.6M
61
AVTXAvalo Therapeutics, Inc.$706.0M
36
VSTMVerastem, Inc.$712.3M
59
FDMT4D Molecular Therapeutics, Inc.$701.6M
56
SLDBSolid Biosciences, Inc.$717.0M
44
MDXGMiMedx Group, Inc.$686.4M
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Candel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CADL news & analysis

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

GlobeNewsWire · 2 Oct 2026positive

Candel Therapeutics announced it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical and mechanistic findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting, held November 4-8, 2026 in Phoenix, Arizona.

Why it matters — The accepted poster presentations give Candel an opportunity to highlight clinical progress on two of its key immunotherapy programs before an oncology audience.

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

Candel Therapeutics announced that on September 30, 2026, its Compensation Committee granted inducement stock options to four new employees to purchase an aggregate of 85,900 shares of common stock at an exercise price of $10.44 per share. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards.

Why it matters — CADL watchers should note the hiring of new employees and the related equity incentive grants, which reflect ongoing company operations and headcount expansion.

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

GlobeNewsWire · 1 Oct 2026positive

Candel Therapeutics announced the publication of final Phase 2a clinical trial results (NCT04495153) showing that aglatimagene besadenovec plus valacyclovir demonstrated prolonged median overall survival of 24.5 months in patients with unresectable Stage III/IV NSCLC who had an inadequate response to immune checkpoint inhibitors. The median overall survival substantially exceeded historical benchmarks for standard-of-care docetaxel chemotherapy in this patient population.

Why it matters — The published data supports the potential of Candel's investigational candidate in a difficult-to-treat NSCLC population and represents a notable clinical milestone for the company.

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

GlobeNewsWire · 30 Sept 2026positive

Candel Therapeutics announced integrated clinical and biomarker data showing durable local and systemic immune activation after aglatimagene besadenovec in intermediate-risk localized prostate cancer. The data come from the phase 2 PrTK05 trial and the intermediate-risk subgroup of the PrTK03 phase 3 trial, and are expected to be presented at a future scientific meeting.

Why it matters — The data point to a potentially new treatment approach addressing unmet needs in the largest group of localized prostate cancer patients treated with curative-intent radiation therapy.

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

GlobeNewsWire · 30 Sept 2026positive

Candel Therapeutics announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in localized intermediate- to high-risk prostate cancer at the ASTRO 2026 Annual Meeting. The data show sustained immune remodeling more than two years after treatment.

Why it matters — This presentation provides new evidence on the durability of the immunotherapy's effects from Candel's completed phase 3 trial, offering CADL watchers insight into the candidate's long-term biomarker profile.

FAQ

Frequently asked questions about CADL stock

What is the CADL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Candel Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $15 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CADL stock a buy right now?

Of the 8 analysts covering Candel Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Candel Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CADL?

As at 8 Oct 2026, Candel Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).

Will CADL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +132.9% from the last close, and Ticker Nerd's factor model ranks Candel Therapeutics, Inc. 41 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CADL stock forecast for 2030?

No analyst covering Candel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CADL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $29 over the next 12 months.

How has CADL stock performed over the past year?

Candel Therapeutics, Inc. returned +53.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Candel Therapeutics, Inc. do?

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer.

What is the latest news on CADL?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Candel Therapeutics to Present at the SITC 2026 Annual Meeting". Candel Therapeutics announced it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical and mechanistic findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting, held November 4-8, 2026 in Phoenix, Arizona.

Company

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. · 55 employees · United States · https://www.candeltx.com